MA58170B1 - Dérivés carboxy avec des proprietes anti-inflammatoires - Google Patents
Dérivés carboxy avec des proprietes anti-inflammatoiresInfo
- Publication number
- MA58170B1 MA58170B1 MA58170A MA58170A MA58170B1 MA 58170 B1 MA58170 B1 MA 58170B1 MA 58170 A MA58170 A MA 58170A MA 58170 A MA58170 A MA 58170A MA 58170 B1 MA58170 B1 MA 58170B1
- Authority
- MA
- Morocco
- Prior art keywords
- inflammatory properties
- carboxy derivatives
- carboxy
- derivatives
- inflammatory
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19219531 | 2019-12-23 | ||
| EP20162545 | 2020-03-11 | ||
| EP20189623 | 2020-08-05 | ||
| EP20205768 | 2020-11-04 | ||
| PCT/GB2020/053357 WO2021130492A1 (en) | 2019-12-23 | 2020-12-23 | Carboxy derivatives with antiinflammatory properties |
| EP20830293.5A EP4081511B3 (en) | 2019-12-23 | 2020-12-23 | Carboxy derivatives with antiinflammatory properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA58170B1 true MA58170B1 (fr) | 2024-10-31 |
Family
ID=74104118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA58170A MA58170B1 (fr) | 2019-12-23 | 2020-12-23 | Dérivés carboxy avec des proprietes anti-inflammatoires |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US12617762B2 (enExample) |
| EP (2) | EP4081511B3 (enExample) |
| JP (2) | JP7679384B2 (enExample) |
| KR (1) | KR20220119425A (enExample) |
| CN (1) | CN115066418B (enExample) |
| AU (1) | AU2020412853A1 (enExample) |
| BR (1) | BR112022011933A2 (enExample) |
| CA (2) | CA3161424C (enExample) |
| CL (1) | CL2022001722A1 (enExample) |
| CO (1) | CO2022008652A2 (enExample) |
| CR (1) | CR20220300A (enExample) |
| DK (1) | DK4081511T6 (enExample) |
| EC (1) | ECSP22049370A (enExample) |
| ES (1) | ES2987014T7 (enExample) |
| FI (1) | FI4081511T6 (enExample) |
| HR (1) | HRP20241378T4 (enExample) |
| HU (1) | HUE068571T2 (enExample) |
| IL (1) | IL293982B2 (enExample) |
| JO (1) | JOP20220162A1 (enExample) |
| LT (1) | LT4081511T (enExample) |
| MA (1) | MA58170B1 (enExample) |
| MD (1) | MD4081511T2 (enExample) |
| MX (1) | MX2022007846A (enExample) |
| PE (1) | PE20221584A1 (enExample) |
| PH (1) | PH12022551546A1 (enExample) |
| PL (1) | PL4081511T6 (enExample) |
| RS (1) | RS66019B1 (enExample) |
| SI (1) | SI4081511T2 (enExample) |
| TW (1) | TWI891696B (enExample) |
| WO (1) | WO2021130492A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL287444B2 (en) | 2019-04-30 | 2024-09-01 | Sitryx Therapeutics Ltd | Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| EP4192821A1 (en) | 2020-08-05 | 2023-06-14 | Sitryx Therapeutics Limited | Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties |
| US12678419B2 (en) | 2020-10-27 | 2026-07-14 | Sitryx Therapeutics Limited | Compounds |
| WO2022229617A1 (en) * | 2021-04-26 | 2022-11-03 | Sitryx Therapeutics Limited | 2-methylene-4-oxo-butanoic acid drivatives for the treatment of inflammation |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2022269251A1 (en) * | 2021-06-22 | 2022-12-29 | Sitryx Therapeutics Limited | Acrylamide derivatives useful as anti-inflammatory agents |
| CN113499453B (zh) * | 2021-07-20 | 2022-10-21 | 徐州医科大学 | 自噬抑制及抗炎联合温合光热诊疗剂及其制备方法与应用 |
| WO2023017269A1 (en) | 2021-08-11 | 2023-02-16 | Sitryx Therapeutics Limited | Derivatives of itaconic acid and their use as anti-inflammatory agents |
| WO2023247958A1 (en) | 2022-06-22 | 2023-12-28 | Sitryx Therapeutics Limited | Oxadiazole derivatives, preparation process thereof and their use in treating inflammatory diseases |
| WO2024089421A1 (en) | 2022-10-25 | 2024-05-02 | Sitryx Therapeutics Limited | Tetrazole derivatives |
| AU2023392783A1 (en) * | 2022-12-15 | 2025-06-19 | Sitryx Therapeutics Limited | Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response |
| KR102864655B1 (ko) * | 2023-01-19 | 2025-09-29 | 대한민국 | 뎅기바이러스 감염에 의한 질환의 예방 또는 치료용 약학적 조성물 |
| CN115819186B (zh) * | 2023-02-14 | 2023-05-16 | 广东银珠医药科技有限公司 | 一种3,5-二氯苯甲醇的新型制备方法 |
| CN117205194A (zh) * | 2023-05-10 | 2023-12-12 | 苏州大学 | 衣康酸或其衍生物在制备预防或治疗急性移植物抗宿主病药物中的应用 |
| CN116725998A (zh) * | 2023-07-20 | 2023-09-12 | 中国科学技术大学 | 特立氟胺在抑制nlrp3炎症小体活化中的应用 |
| CN118812769B (zh) * | 2024-07-02 | 2025-09-26 | 南京工业大学 | 一种衣康酰肼诱导的Janus结构聚合物表皮贴片电极及其制备方法 |
| CN119792264B (zh) * | 2025-03-14 | 2025-06-10 | 华中科技大学同济医学院附属同济医院 | 丁酰肼在制备预防或治疗copd的药物中的应用 |
| CN120585811B (zh) * | 2025-08-07 | 2026-01-06 | 华南理工大学 | 4-辛基衣康酸在制备改善肺动脉高压的药物中的应用 |
| CN121668151A (zh) * | 2026-02-11 | 2026-03-17 | 武汉大学人民医院（湖北省人民医院） | 衣康酸类化合物在制备治疗视网膜动脉阻塞药物中的用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1963672A1 (de) | 1969-12-19 | 1971-06-24 | Hoechst Ag | Dithiophosphorsaeureester,ihre Herstellung und Anwendung als Schaedlingsbekaempfungsmittel |
| DE2047465A1 (de) | 1970-09-26 | 1972-03-30 | Farbwerke Hoechst AG, vorm Meister Lucius & Bruning, 6000 Frankfurt | Neue Oxdiazole und Verfahren zu lh rer Herstellung |
| NL7413713A (nl) | 1973-11-02 | 1975-05-07 | Ciba Geigy | Werkwijze voor het bereiden van nieuwe esters. |
| DE2805756A1 (de) | 1978-02-10 | 1979-08-16 | Bayer Ag | N-azolylalkyl-aniline sowie verfahren zu ihrer herstellung |
| JPS6212776A (ja) | 1985-07-10 | 1987-01-21 | Taiho Yakuhin Kogyo Kk | ロ−ダニン誘導体 |
| EP0521622B1 (en) | 1991-07-03 | 1997-08-13 | PHARMACIA & UPJOHN COMPANY | Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories |
| EP0724573A1 (en) * | 1993-10-20 | 1996-08-07 | PHARMACIA & UPJOHN COMPANY | Pyrimidinones as antiarthritic and anti-inflammatories |
| US6566384B1 (en) | 1996-08-07 | 2003-05-20 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity |
| KR100538968B1 (ko) | 1997-02-18 | 2006-07-11 | 후지 샤신 필름 가부시기가이샤 | 포지티브감광성조성물 |
| US5965718A (en) | 1997-10-24 | 1999-10-12 | The Scripps Research Institute | Analogs of sarcodictyin and eleutherobin |
| JP2001354625A (ja) | 2000-04-12 | 2001-12-25 | Dainippon Ink & Chem Inc | 新規なイタコン酸エステル及びその製造方法 |
| JP4102014B2 (ja) | 2000-10-03 | 2008-06-18 | 富士フイルム株式会社 | 感光性平版印刷版 |
| JP2004315791A (ja) | 2003-03-28 | 2004-11-11 | Tokyo Ohka Kogyo Co Ltd | ジカルボン酸モノエステル化合物およびその製造方法ならびに重合体 |
| TW201206429A (en) | 2010-07-08 | 2012-02-16 | Merck Serono Sa | Substituted oxadiazole derivatives |
| US8637536B2 (en) * | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
| MX386935B (es) | 2013-03-14 | 2025-03-04 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. |
| WO2014152263A1 (en) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| AU2014290368B2 (en) * | 2013-07-18 | 2019-07-11 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| CN103923105B (zh) * | 2014-04-17 | 2016-08-24 | 北京大学 | 2-中氮茚甲酰胺类化合物及其制备和用途 |
| EP3416634A4 (en) | 2016-02-15 | 2019-10-09 | Artyomov, Maxim | IMMUNOMODULATORY AGENTS AND METHOD FOR USE THEREOF |
| US20200375929A1 (en) | 2017-08-14 | 2020-12-03 | Washington University | Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response |
| WO2019066827A1 (en) | 2017-09-27 | 2019-04-04 | Intel Corporation | CHARACTERISTICS AND APPROACHES TO GRID ASSISTANCE FOR ELECTRON BEAM DIRECT WRITE LITHOGRAPHY (EBDW) |
| EP3813815B1 (en) | 2018-06-29 | 2026-01-28 | Ergon Pharmaceuticals, LLC | Compositions and methods of using itaconic acid derivatives |
| IL287444B2 (en) | 2019-04-30 | 2024-09-01 | Sitryx Therapeutics Ltd | Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response |
| US20200377510A1 (en) * | 2019-05-30 | 2020-12-03 | Auransa Inc. | Derivatives of piperlongumine and uses thereof |
| CN110731955B (zh) | 2019-10-28 | 2023-05-02 | 中山大学 | 衣康酸二甲酯在预防和治疗溃疡性结肠炎及其癌变中的应用 |
| EP4192821A1 (en) | 2020-08-05 | 2023-06-14 | Sitryx Therapeutics Limited | Alpha,beta unsaturated methacrylic esters with anti-inflammatory properties |
| EP4200275A2 (en) | 2020-08-21 | 2023-06-28 | Sitryx Therapeutics Limited | Fumarate derivatives and their medical use |
| US12678419B2 (en) | 2020-10-27 | 2026-07-14 | Sitryx Therapeutics Limited | Compounds |
| EP4237408A1 (en) | 2020-10-29 | 2023-09-06 | Sitryx Therapeutics Limited | Itaconic acid derivatives |
| EP4237404A1 (en) | 2020-10-29 | 2023-09-06 | Sitryx Therapeutics Limited | Novel compounds |
-
2020
- 2020-12-23 FI FIEP20830293.5T patent/FI4081511T6/fi active
- 2020-12-23 HR HRP20241378TT patent/HRP20241378T4/hr unknown
- 2020-12-23 BR BR112022011933A patent/BR112022011933A2/pt unknown
- 2020-12-23 MA MA58170A patent/MA58170B1/fr unknown
- 2020-12-23 CR CR20220300A patent/CR20220300A/es unknown
- 2020-12-23 EP EP20830293.5A patent/EP4081511B3/en active Active
- 2020-12-23 IL IL293982A patent/IL293982B2/en unknown
- 2020-12-23 MD MDE20221214T patent/MD4081511T2/ro unknown
- 2020-12-23 JP JP2022538727A patent/JP7679384B2/ja active Active
- 2020-12-23 ES ES20830293T patent/ES2987014T7/es active Active
- 2020-12-23 CA CA3161424A patent/CA3161424C/en active Active
- 2020-12-23 WO PCT/GB2020/053357 patent/WO2021130492A1/en not_active Ceased
- 2020-12-23 MX MX2022007846A patent/MX2022007846A/es unknown
- 2020-12-23 PL PL20830293.5T patent/PL4081511T6/pl unknown
- 2020-12-23 HU HUE20830293A patent/HUE068571T2/hu unknown
- 2020-12-23 EP EP24183456.3A patent/EP4442319A3/en not_active Withdrawn
- 2020-12-23 SI SI202030480T patent/SI4081511T2/sl unknown
- 2020-12-23 DK DK20830293.5T patent/DK4081511T6/da active
- 2020-12-23 RS RS20241087A patent/RS66019B1/sr unknown
- 2020-12-23 PE PE2022001159A patent/PE20221584A1/es unknown
- 2020-12-23 AU AU2020412853A patent/AU2020412853A1/en active Pending
- 2020-12-23 PH PH1/2022/551546A patent/PH12022551546A1/en unknown
- 2020-12-23 TW TW109145642A patent/TWI891696B/zh active
- 2020-12-23 LT LTEPPCT/GB2020/053357T patent/LT4081511T/lt unknown
- 2020-12-23 KR KR1020227024819A patent/KR20220119425A/ko active Pending
- 2020-12-23 CN CN202080083315.0A patent/CN115066418B/zh active Active
- 2020-12-23 CA CA3280359A patent/CA3280359A1/en active Pending
- 2020-12-23 US US17/787,870 patent/US12617762B2/en active Active
-
2022
- 2022-06-21 JO JOP/2022/0162A patent/JOP20220162A1/ar unknown
- 2022-06-21 CO CONC2022/0008652A patent/CO2022008652A2/es unknown
- 2022-06-21 EC ECSENADI202249370A patent/ECSP22049370A/es unknown
- 2022-06-22 CL CL2022001722A patent/CL2022001722A1/es unknown
-
2025
- 2025-05-07 JP JP2025077120A patent/JP2025131581A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA45020B1 (fr) | Dérivés sulfonamides aromatiques | |
| MA54538B1 (fr) | Inhibiteurs d'apol1 et leurs procédés d'utilisation | |
| MA33606B1 (fr) | Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 | |
| MA34299B1 (fr) | Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2 | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| PH12022551546A1 (en) | Carboxy derivatives with antiinflamatory properties. | |
| JOP20230186A1 (ar) | أجسام مضادة لـ cd30l واستخداماتها | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
| MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA51837B1 (fr) | Inhibiteurs de l'arginase et leurs procédés d'utilisation | |
| MA32282B1 (fr) | Dérivés de 2-phényl-pyridine substitués | |
| FR3065642B1 (fr) | Utilisation de 20-hydroxyecdysone et ses derives dans le traitement des myopathies | |
| MA35443B1 (fr) | Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| MA50069B1 (fr) | Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique | |
| MA53707A (fr) | Dérivés d'indane destinés à être utilisés dans le traitement d'une infection bactérienne | |
| CA3156131A1 (en) | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | |
| MA30662B1 (fr) | Derives de phenyl-prenyl-ether pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux |